Introduction to Cervical Cancer Olive

23
Dr Olive Sentumbwe-Mugisa Family Health and Population Advisor:WHO

Transcript of Introduction to Cervical Cancer Olive

Page 1: Introduction to Cervical Cancer Olive

Dr Olive Sentumbwe-MugisaFamily Health and Population Advisor:WHO

Page 2: Introduction to Cervical Cancer Olive

Cervix

UterusOvary

Vagina

Page 3: Introduction to Cervical Cancer Olive

This is the uncontrolled growth of some cells on the cervix [the mouth of the womb]. Cells on the cervix begin to grow slowly and abnormally over several years.

◦ These early (pre-cancerous) changes can grow

into cancer if they are not identified [screening] and treated early.

Page 4: Introduction to Cervical Cancer Olive

Symptom free- Women are usually healthy looking and the condition is usually painless in early stages

Irregular / intermenstrual or contact vaginal bleeding

Foul vaginal discharge that never improves with treatment

Pain (deep pelvic or back pain) In advanced cases; severe anaemia, renal

failure, fistulae (rectal/vesico-vaginal), lymphoedema

Page 5: Introduction to Cervical Cancer Olive
Page 6: Introduction to Cervical Cancer Olive

Magnitude of Cervical Cancer in Uganda: Actual magnitude is unknown-no national

data Cacx data not captured by HMIS National cancer registry-covers Kyaddondo county

Among female cancers-◦ Cervical cancer accounts for 40% of cancers ◦ Breast cancer accounts for 23%◦ Others account for 37%◦ Cacx accounts for over 80% of female cancers

Page 7: Introduction to Cervical Cancer Olive

Clinical Reports ◦ Cervical cancer patients occupy 30% - 50% of

Gyne beds at Mulago & RRH .

◦ Over 80% of women with cacx are diagnosed with advanced disease. Stage III.

◦ Over 40% of radiotherapy patients have cacx.◦ From admission to diagnosis is 2 to 4 weeks.

Page 8: Introduction to Cervical Cancer Olive

◦ Leading cause of Gynaecological deaths◦ Almost all cases advanced.◦ Facilities to screen and treat are limited.◦ Skills to diagnose & treat are limited as

most cases are missed as STIs.◦ The symptoms are mistaken with those of

other gyne conditions◦ Women suffer silently and do not report◦ Only about 5% of women ever get access to

screening.

Page 9: Introduction to Cervical Cancer Olive

Human papillomavirus (HPV) types 16 & 18.

99.7% of cervical cancer cases are associated with HPV

Progression from HPV infection to cancer usually takes about 15 years

Page 10: Introduction to Cervical Cancer Olive

Early age at first sexual intercourse◦ Multiple sexual partners◦ Wives in polygamous unions◦ All risky sexual behavior◦ smoking◦ Any women who have ever had sex◦ All those above 25 years up to 60.

Page 11: Introduction to Cervical Cancer Olive

Prevalence of high-risk HPV infection No organized screening programs,

despite many efforts “Competing” health problems Limited awareness of cost effective

approaches to prevention Until recently, no vaccine was available

to prevent infection Symptom free and goes unnoticed till

late

Page 12: Introduction to Cervical Cancer Olive

Education & awareness Main stay is regular screening;

◦ Screening options Pap smear - annually HPV testing – used inconjunction with Pap or

alone Visual inspection of cervix with 5% acetic

acid/lugol’s iodine – every 3 years◦ Colposcopy/biopsy – used with above 3

Treatment of pre-cancer (cryotherapy, LEEP),

For early invasive cacx (surgery, radiotherapy),

For inoperable disease (Radiotherapy, Palliative care)

Page 13: Introduction to Cervical Cancer Olive

Commitment:◦ Lack of prioritization of women's sexual &

Reproductive Health ◦ Failure to allocate resources to Cervical &

other Cancers’ control programs.◦ Lack of enabling policies & evidence based

guidelines◦ Competing priorities- ? HIV, TB, Malaria?

Inability to scale up & sustain pilot screening projects inspite of available evidence.

Lack of commitment from policy makers to prioritize cancer control.

Page 14: Introduction to Cervical Cancer Olive

Lack of awareness that Cervical Cancer and other RH cancers are a major health problem among the population, health care providers' leaders & policy makers.

Poor attitudes, misconceptions & beliefs that cancer is untreatable & therefore a death sentence. [stigma surrounding diseases of genital tract].

Failure to openly discuss issues related to sex & diseases of the genital tract presents major barriers to RH & cervical cancer control.

Lack of symptoms at stages where treatment is effective.

Page 15: Introduction to Cervical Cancer Olive

Weaknesses in health systems,◦ Equipment maybe locked up◦ Lack of facilitative supervision◦ HMIS not capturing cancer data-burden unknown!◦ Failure of H/W to recognize cacx as a big problem

lack of appropriate equipment, and

Lack of skills among providers limits access to prevention activities, screening, diagnosis treatment, follow up and palliative care.

Page 16: Introduction to Cervical Cancer Olive

RH policy & Service standards Policy goal is to enhance integration of

services for; Screening cervical & breast cancers Treatment of RH cancers in both men &

women

Page 17: Introduction to Cervical Cancer Olive

The WHO/MoH are on Masaka pilot [VIA] project (12 months)

UCL-Uganda Women’s Health Initiative in peri-urban Kampala. ◦ University college-London ◦ Project is for 3 years◦ Ongoing for 20 months & screened 3500 women [VIA/VILI].◦ Working with PATH & MoH on National Scale up plans for cervical cancer

prevention.

PATH on the Cervical Cancer Vaccine project & already supporting Secondary prevention and National scale up plan

IEC & Advocacy

Others are ◦ University based researchers ◦ Association of Obstetricians & Gynaecologists of Uganda

Page 18: Introduction to Cervical Cancer Olive

CervicalScreeningProtocol

VisualInspection

Lugols Iodine

VisualInspectionAcetic acid

CervicalCytology

(Pap Smear)

Colposcopy

Cryotherapy

ABNORMAL ABNORMAL

Page 19: Introduction to Cervical Cancer Olive

Two vaccines proven effective: [cervarix & gardasil]

5 Year project – 2006 to 2011 6 - main activities

• Formative Research• Demonstration project • Financial analysis• Secondary prevention – National scale-up• Advocacy and communication• Financial analysis

Funding from Bill & Melinda Gates Foundation (BMGF)

Page 20: Introduction to Cervical Cancer Olive

Objective:To strengthen the capacity of developing countries to prevent cervical cancer through generating and providing necessary evidence about public-sector introduction of cervical cancer vaccines. PATH picture

PA

TH

pic

ture

Page 21: Introduction to Cervical Cancer Olive

1. Formative Research – ongoing

(Gulu, Soroti, Kampala, Masaka, Mbarara)◦ Social cultural – Knowledge, Attitudes◦ Delivery options and systems◦ Policy analysis◦ Advocacy strategy ◦ Communication design

Page 22: Introduction to Cervical Cancer Olive

Objective: To assess feasibility of school-based strategy for reaching girls in school aged 10-12 years, plus additional strategy for reaching girls out of school, possibly synchronized with semi-annual Child Health Days

Primary outcome: 3-dose vaccination coverage in each group

Secondary outcomes: ◦ 1- and 2-dose vaccination coverage◦ Vaccination drop-out rate◦ Cost of each strategy◦ Acceptability (KAP) among

recipients, families

Page 23: Introduction to Cervical Cancer Olive

THANK YOU FOR LISTENING TO THIS PRESENTATION.

DISCUSSION&

WAYFORWARD